# Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

> **NCT01177397** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 226 (actual)

## Conditions studied

- Multiple Myeloma
- Diffuse Large B-Cell Lymphoma
- Glioblastoma Multiforme
- Hepatocellular Carcinoma
- Non-Small Cell Lung Cancer
- Neuroendocrine Tumors of Non-Pancreatic Origin
- Hormone Receptor-Positive Breast Cancer

## Interventions

- **DRUG:** CC-223

## Key facts

- **NCT ID:** NCT01177397
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-20
- **Primary completion:** 2016-11-15
- **Final completion:** 2016-12-09
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2022-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177397, "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01177397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*